The medicines business | A question to investigate
Public medicines data. A sharper commercial question.
Public medicines data can tell a compelling story. It can also support a misleading one if dispensing, expenditure, shortages and commercial sales are treated as the same thing. NEUVIOR’s interest is to turn an available dataset into a better business question: what does the source actually measure, which decision can it inform, and what additional evidence would be needed before an organisation acts?
In the conversation.
NEUVIOR and our founder’s perspectives have appeared across science, business and technology publications.
Reporting, commentary, letters and podcast appearances | Read each feature for its format and source.
Begin with a decision, not a dashboard
A manufacturer might be considering a product category. A wholesaler might want to understand a change in published activity. An industry strategy team might be deciding which uncertainty deserves further investigation. These are different questions with different evidential demands. A proposed public-data review would specify one decision, its geography and time horizon before selecting sources. A large collection of charts is not inherently useful when the intended decision remains vague.
Know what each source can support
NHSBSA’s PCA describes community dispensing items and net ingredient cost in England (NHSBSA, n.d.). FDA provides a public drug-shortages API (FDA, n.d.). The sources concern different jurisdictions and measures. Neither is a complete market database or a live inventory feed. Any proposed analysis would preserve those distinctions and publication dates. It would not infer a manufacturer’s revenue, net selling price, available capacity or customer relationships from an aggregate public series.
Make a comparison that stays interpretable
A change in spending may reflect price, volume, product mix or a change in coverage. A count of items does not necessarily mean the same treatment duration across presentations. Comparing countries can add differences in coding, reimbursement and care setting. A useful brief should describe which comparisons are valid and which remain exploratory. Sometimes the most valuable result is to identify why two attractive-looking numbers should not be placed on the same axis.
A view that shows where interpretation ends
The proposed deliverable would pair an interactive comparison with a short account of its denominator, transformations and excluded inferences. A reader could inspect the evidence behind a finding and see the information still needed for a business decision. The value would come from disciplined interpretation, rather than the number of datasets displayed.
A public decision brief | An illustrative example
Open the question.
Inspect the reasoning.
Choose a business question, then look beneath its claim. See what a public source supports, what depends on the local setting and what a useful next step could be.
A medicines or implementation team considering an AI-supported evidence review.
Would a quicker review make the decision better?
The interesting question is the complete piece of work: finding relevant material, checking it, correcting the draft and reaching an accountable decision.
A proposition to investigate
Less preparation. The same ability to challenge.
An evidence-review approach could be useful if it reduces avoidable preparation while preserving source access, relevant qualifications and professional checking. That is the proposed value to test. No time reduction, accuracy improvement or customer result is asserted in this example.
The proposition is constructed for this public brief. It is not a published finding about PHARMORIS.
What the next brief would contain
A decision someone
can commission.
- The decision
- Whether one defined review task merits an agreed evaluation.
- The comparator
- The team's existing complete review process, including checking and corrections.
- The evidence
- Representative cases, source records, reviewer decisions, complete-task effort and exceptions.
- Stop or redesign
- Stop or redesign if source checking weakens, errors are unacceptable or the complete task offers insufficient value.
Constructed public example | Not PHARMORIS-generated software output or a measured customer result.
Keep this example briefA proposed PHARMORIS evaluation
We would select a bounded question and a small set of official sources with accessible definitions. Inputs would include dated source extracts, documented transformations and the organisation’s stated decision criteria. The comparator could be the existing market-scoping brief. Reviewers would assess whether a proposed interactive view improves interpretation and makes exclusions easier to understand. It would be a test of analytical usefulness, not an assertion that PHARMORIS has an established global-data capability.
Useful measures for a public-data product
Candidate outcomes include whether users correctly identify the denominator, distinguish a descriptive finding from a commercial inference and locate the supporting source. The evaluation could also measure reproducibility and the effort needed to update the analysis when a source changes. Engagement alone is insufficient: an animated chart that increases confidence in a wrong interpretation is a poor result. The product should earn attention by helping someone ask and answer a more precise question.
The boundary of the first offer
We would stop if the decision requires information absent from the public sources, if licensing does not support the intended use, or if source definitions cannot be reconciled. A public-data review may justify a later confidential discussion, but it should not imply access to private procurement prices or patient-level records. A commercial offer needs a deliverable the buyer can use and evidence of willingness to pay; a collection of freely available statistics does not establish either.
Bring a decision that public evidence might inform
A strategy or commercial leader can bring one product, category or geography question and explain what action would follow a credible answer. We can discuss the available official evidence, the limits of interpretation and the shape of a small evaluation. The opportunity is to make public information useful within a commercial decision, while keeping the source, reasoning and unanswered questions visible enough for a sceptical reviewer to challenge.
Sources and scope
NHSBSA | Prescription Cost Analysis England | FDA | Drug shortages API
NHSBSA (n.d.) Prescription Cost Analysis England. Available at: https://www.nhsbsa.nhs.uk/statistical-collections/prescription-cost-analysis-england (Accessed: 14 October 2026).
FDA (n.d.) Drug shortages API. Available at: https://open.fda.gov/apis/drug/drugshortages/how-to-use-the-endpoint/ (Accessed: 14 October 2026).
Another useful angle.
- Access is a decision. Adoption is a journey.
Explore a proposed industry review of local medicines implementation, capacity assumptions and evidence for market-access decisions.
- Can the available data answer the question?
A proposed feasibility review for industry real-world evidence studies, with a clear question, comparator and data-fit decision.
- From a changed document to a clear next question
A proposed regulatory-intelligence triage review connecting official changes, product relevance and accountable assessment.